Fox Chase Cancer Center News

PHILADELPHIA (August 23, 2021)—Fox Chase Cancer Center is proud to announce the opening of a new Prostate & Urologic Cancer Program at its Fox Chase Cancer Center East Norriton - Hospital Outpatient Center.

PHILADELPHIA (August 18, 2021)—Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, was recently awarded a Specialized Program of Research Excellence (SPORE) grant of $50,000 for a pilot project examining differences in risk and disease course for Black versus white head and neck cancer patients.

PHILADELPHIA (August 17, 2021) - Fox Chase Cancer Center is proud to be a local sponsor and continued supporter of the annual Miles for Melanoma Philadelphia 5K, which will take place both in person and online this year.

PHILADELPHIA (August 13, 2021) – Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, has been appointed chair of the Cancer, Heart, and Sleep Epidemiology B Study Section, a committee that will review grant applications submitted to the National Institutes of Health (NIH).

PHILADELPHIA (August 12, 2021) – Namrata “Neena” Vijayvergia, MD, assistant chief of Gastrointestinal Medical Oncology at Fox Chase Cancer Center, has received funding from the National Comprehensive Cancer Network (NCCN) to evaluate neratinib, also known by its brand name Nerlynx, in combination with another drug for the treatment of refractory gastric and esophageal cancer.

PHILADELPHIA (August 6, 2021)—David S. Weinberg, MD, MSc, chair of the Department of Medicine at Fox Chase Cancer Center, was recently named one of two new editors-in-chief of Gastroenterology.

PHILADELPHIA (July 23, 2021) – The percentage of inflammatory breast cancer (IBC) patients selecting reconstructive surgery after mastectomy, whether immediate or delayed, remains low in spite of improvements in treatment and long-term survival, but the numbers are increasing, according to recent research.

PHILADELPHIA (July 23, 2021)—Researchers at Fox Chase Cancer Center recently conducted a mouse model study showing that tumor size can be reduced in cases of neurofibromatosis type 2 (NF2) by targeting PAK1, a gene that regulates cell motility and morphology. PAKs are members of the p21-activated kinase family represented by six genes (PAK1-6).